Share on StockTwits

Sucampo Pharmaceuticals (NASDAQ:SCMP) issued its quarterly earnings data on Wednesday. The company reported $0.02 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.04 by $0.02, AnalystRatingsNetwork.com reports. The company had revenue of $22.20 million for the quarter, compared to the consensus estimate of $24.19 million. Sucampo Pharmaceuticals’s revenue was up 31.4% compared to the same quarter last year.

In other Sucampo Pharmaceuticals news, major shareholder S&R Technology Holdings, Llc sold 113,600 shares of the stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $6.65, for a total transaction of $755,440.00. Following the completion of the transaction, the insider now directly owns 22,820,802 shares of the company’s stock, valued at approximately $151,758,333. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

SCMP has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $8.33.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 7.51% during mid-day trading on Wednesday, hitting $7.30. The stock had a trading volume of 265,664 shares. Sucampo Pharmaceuticals has a 52-week low of $5.40 and a 52-week high of $11.00. The stock has a 50-day moving average of $6.9 and a 200-day moving average of $7.80. The company has a market cap of $312.4 million and a price-to-earnings ratio of 45.27.

Sucampo Pharmaceuticals, Inc is a pharmaceutical Company. The Company is focused on the discovery, development and commercialization of drugs based on prostones.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.